PC
ITCI

Polar Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Polar Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$3.85M Buy
+150,000
New +$3.42M 0.03% 221

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Polar Capital's ITCI Position: Q3 2020 in Review

Polar Capital opened a new position in Intra-Cellular Therapies Inc. (ITCI) in Q3 2020: 150,000 shares worth $3.85M. The stake represents 0.03% of the portfolio and ranks #221 among its holdings.

176 funds tracked by Wall St. Rank hold ITCI as of Q3 2020.

  • Polar Capital held 150,000 shares of Intra-Cellular Therapies Inc. worth $3.85M as of Q3 2020.
  • Intra-Cellular Therapies Inc. was a new Polar Capital position in Q3 2020.
  • Intra-Cellular Therapies Inc. made up 0.03% of Polar Capital's portfolio in Q3 2020, its #221 holding.
  • 176 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.